319 related articles for article (PubMed ID: 35174479)
1. Current challenges in the treatment of cardiac fibrosis: Recent insights into the sex-specific differences of glucose-lowering therapies on the diabetic heart: IUPHAR Review 33.
Sharma A; De Blasio M; Ritchie R
Br J Pharmacol; 2023 Nov; 180(22):2916-2933. PubMed ID: 35174479
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targets of fibrosis: Translational advances and current challenges.
De Blasio MJ; Ohlstein EH; Ritchie RH
Br J Pharmacol; 2023 Nov; 180(22):2839-2845. PubMed ID: 37846458
[TBL] [Abstract][Full Text] [Related]
3. Preclinical rodent models of cardiac fibrosis.
Wang Y; Wang M; Samuel CS; Widdop RE
Br J Pharmacol; 2022 Mar; 179(5):882-899. PubMed ID: 33973236
[TBL] [Abstract][Full Text] [Related]
4. FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy.
Zhang Y; Edgley AJ; Cox AJ; Powell AK; Wang B; Kompa AR; Stapleton DI; Zammit SC; Williams SJ; Krum H; Gilbert RE; Kelly DJ
Eur J Heart Fail; 2012 May; 14(5):549-62. PubMed ID: 22417655
[TBL] [Abstract][Full Text] [Related]
5. Progress in the treatment of diabetic cardiomyopathy, a systematic review.
Shou Y; Li X; Fang Q; Xie A; Zhang Y; Fu X; Wang M; Gong W; Zhang X; Yang D
Pharmacol Res Perspect; 2024 Apr; 12(2):e1177. PubMed ID: 38407563
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus.
Nakamura K; Miyoshi T; Yoshida M; Akagi S; Saito Y; Ejiri K; Matsuo N; Ichikawa K; Iwasaki K; Naito T; Namba Y; Yoshida M; Sugiyama H; Ito H
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408946
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction.
Alex L; Russo I; Holoborodko V; Frangogiannis NG
Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H934-H949. PubMed ID: 30004258
[TBL] [Abstract][Full Text] [Related]
8. Reverse remodeling in diabetic cardiomyopathy: the role of extracellular matrix.
Aykac I; Podesser BK; Kiss A
Minerva Cardiol Angiol; 2022 Jun; 70(3):385-392. PubMed ID: 34713679
[TBL] [Abstract][Full Text] [Related]
9. Argatroban Attenuates Diabetic Cardiomyopathy in Rats by Reducing Fibrosis, Inflammation, Apoptosis, and Protease-Activated Receptor Expression.
Bulani Y; Sharma SS
Cardiovasc Drugs Ther; 2017 Jun; 31(3):255-267. PubMed ID: 28695302
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of cardiac pathology in diabetes - Experimental insights.
Varma U; Koutsifeli P; Benson VL; Mellor KM; Delbridge LMD
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt B):1949-1959. PubMed ID: 29109032
[TBL] [Abstract][Full Text] [Related]
11. Chronic liver diseases: From development to novel pharmacological therapies: IUPHAR Review 37.
Borrello MT; Mann D
Br J Pharmacol; 2023 Nov; 180(22):2880-2897. PubMed ID: 35393658
[TBL] [Abstract][Full Text] [Related]
12. The role of hyperglycaemia in the development of diabetic cardiomyopathy.
El Hayek MS; Ernande L; Benitah JP; Gomez AM; Pereira L
Arch Cardiovasc Dis; 2021 Nov; 114(11):748-760. PubMed ID: 34627704
[TBL] [Abstract][Full Text] [Related]
13. Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy.
Wang L; Cai Y; Jian L; Cheung CW; Zhang L; Xia Z
Cardiovasc Diabetol; 2021 Jan; 20(1):2. PubMed ID: 33397369
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular characterisation of a novel mouse model that combines hypertension and diabetes co-morbidities.
Sharma A; Choi JSY; Watson AMD; Li L; Sonntag T; Lee MKS; Murphy AJ; De Blasio M; Head GA; Ritchie RH; de Haan JB
Sci Rep; 2023 May; 13(1):8741. PubMed ID: 37253814
[TBL] [Abstract][Full Text] [Related]
15. The Role of Cardiac Fibrosis in Diabetic Cardiomyopathy: From Pathophysiology to Clinical Diagnostic Tools.
Pan KL; Hsu YC; Chang ST; Chung CM; Lin CL
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239956
[TBL] [Abstract][Full Text] [Related]
16. Clinical Approach to Diabetic Cardiomyopathy: A Review of Human Studies.
Tarquini R; Pala L; Brancati S; Vannini G; De Cosmo S; Mazzoccoli G; Rotella CM
Curr Med Chem; 2018; 25(13):1510-1524. PubMed ID: 28685679
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes.
Prakoso D; De Blasio MJ; Tate M; Kiriazis H; Donner DG; Qian H; Nash D; Deo M; Weeks KL; Parry LJ; Gregorevic P; McMullen JR; Ritchie RH
Am J Physiol Heart Circ Physiol; 2020 Apr; 318(4):H840-H852. PubMed ID: 32142359
[TBL] [Abstract][Full Text] [Related]
18. Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis.
Ohm B; Moneke I; Jungraithmayr W
Br J Pharmacol; 2023 Nov; 180(22):2846-2861. PubMed ID: 36196001
[TBL] [Abstract][Full Text] [Related]
19. Understanding One Half of the Sex Difference Equation: The Modulatory Effects of Testosterone on Diabetic Cardiomyopathy.
Visanji M; Venegas-Pino DE; Werstuck GH
Am J Pathol; 2024 Apr; 194(4):551-561. PubMed ID: 38061627
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide alleviates cardiac fibrosis through inhibiting P4hα-1 expression in STZ-induced diabetic cardiomyopathy.
Zhao T; Chen H; Xu F; Wang J; Liu Y; Xing X; Guo L; Zhang M; Lu Q
Acta Biochim Biophys Sin (Shanghai); 2019 Mar; 51(3):293-300. PubMed ID: 30883649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
